Abstract:Yongkang Zhang, &ast Jiarui Liu, &ast Yuzhen Wang, Yuan Zong, Kangli Yin, Fang Cao, Xinyu Liang, Yemin Cao Diagnosis and Treatment Center of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yemin Cao; Yongkang Zhang, Diagnosis and Treatment Center of Vascular Disease, Shanghai TCM-Integrated Hospital, No. 230 Baoding Road, Hongkou District, Shanghai, People's Republic of China, Tel +8613361831119 ; +8613761921568, Email ; Purpose: Peripheral arterial disease (PAD) is a chronic ischemic disease caused by atherosclerosis of the lower extremities, with early clinical symptoms manifesting mainly as intermittent claudication. Current treatment of PAD is based on the control of cardiovascular risk factors. However, even vasoactive drugs are not ideal for improving ischemic symptoms in the lower limbs of PAD patients. Ruanjian Qingmai granules, derived from the classic formula of the late Professor Jiuyi Xi, a famous traditional Chinese medicine doctor in Shanghai, have good clinical efficacy in the treatment of the pattern of blood vessel stasis and obstruction of PAD and have been used by more than 600,000 PAD patients over the past three decades. This study aims to evaluate the efficacy and safety of Ruanjian Qingmai granules in patients with symptomatic PAD. Patients and methods: A prospective, center-randomized, double-blind, placebo-controlled clinical trial will be conducted at 9 grade A tertiary hospitals in Shanghai. It is anticipated that 250 patients with early symptomatic PAD will be recruited and randomized to the control and intervention groups (1:1 ratio of central randomization). Subjects will be treated with Ruanjian Qingmai granules or placebo at 6 g twice daily for 16 weeks. The primary efficacy indicators are the pain-free walking distance and maximum walking distance. The secondary efficacy indicators are the ankle-brachial index, walking impairment questionnaire, quality of life score, and Chinese medicine syndrome score. Conclusion: Positive results from this study will demonstrate the efficacy and safety of Ruanjian Qingmai granules in improving ischemic symptoms in patients with symptomatic PAD. Clinical Registration: This study has been registered with the Chinese Clinical Trials Registry (ChiCTR2200056109, Date: 02/01/2022, https://www.chictr.org.cn/showproj.html?proj=150982 ). Keywords: peripheral arterial disease, Ruanjian Qingmai granules, intermittent claudication, efficacy, randomized controlled trial, protocol Peripheral arterial disease (PAD) is a chronic progressive disease caused by inadequate blood flow to the lower extremities due to atherosclerosis, often leading to adverse clinical outcomes such as refractory ischemic ulcers or amputation. 1 PAD currently affects more than 200 million people worldwide 2 and typically presents with intermittent claudication, rest pain, and critical limb ischemia. 3 As a chronic disease with insidious onset, sudden changes in condition, and poor prognosis, 4 timely intervention and treatment at an early stage to prevent further worsening of limb ischemia is a critical clinical issue that needs to be addressed today. Early PAD is difficult to detect or diagnose because of its insidious symptoms. Patients with symptomatic PAD are a group of patients with typical or atypical clinical symptoms in early PAD. The main treatment methods for patients with early symptomatic PAD are exercise therapy, pharmacological control, and revascularization. 5 Exercise therapy, the first-line therapy to improve intermittent claudication, is difficult to achieve due to poor patient compliance. 6 Vasoactive drugs aimed at improving walking impairment in patients with symptomatic PAD, such as cilostazol, beraprost sodium, and pentoxifylline, are not as effective as they could be. 7,8 In a randomized controlled clinical trial, the effect of 6 months of treatment with beraprost sodium was not significantly different from the placebo group. 9 Another study showed that patients treated concomitantly with rivaroxaban and aspirin had a significantly higher risk of major bleeding, although the incidence of critical limb ischemia was reduced. 10 Similarly, a study with a 3-year follow-up found that revascularization for intermittent claudication in patients with symptomatic PAD provided no additional early benefit and even increased the risk of amputation in some patients. 11 Therefore, the aim of this study was to find new treatment options that can be applied in addition to existing th -Abstract Truncated-

SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial

A New Drug-Coated Balloon for the Treatment of Superficial Femoropopliteal Artery Disease: 12-Month Results from the IN-DEPT SFA Trial

IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population

Drug‐coated Balloon for the Treatment of Small Vessel Disease: 9 Months of Angiographic Results and 12 Months of Clinical Outcomes of the PEPCAD China SVD Study

Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial

Rapid reduction in plaque inflammation by sonodynamic therapy inpatients with symptomatic femoropopliteal peripheral artery disease:A randomized controlled trial

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

A Sham-Controlled Randomised Trial of Pulmonary Artery Denervation for Group 1 Pulmonary Arterial Hypertension: One-Year Outcomes of the PADN-CFDA Trial

A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions

Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial

High-Dose Drug-Coated Balloon Versus Polymer-Based Drug-Eluting Stent for Femoropopliteal Artery Disease Treatment

Ruanjian Qingmai Granules for the Treatment of Early Symptomatic Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Protocol

Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease

[Dual pathway inhibition in peripheral arterial disease]

Single Center Outcomes of Percutaneous Deep Vein Arterialization in Patients with End-Stage Peripheral Artery Disease

Label extension, single-arm, phase III study shows efficacy and safety of stempeucel® in patients with critical limb ischemia due to atherosclerotic peripheral arterial disease

First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study

Clinical use of femoral artery hemostasis sticking after interventional procedure via femoral artery access

Randomized Trial Comparing a Stent-Avoiding With a Stent-Preferred Strategy in Complex Femoropopliteal Lesions

Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients